ArticleJournal of clinical laboratory analysis2025
Assessment of Factors Contributing to Infection Severity and High Levels of Drug Resistance in Clinical Enterococcus Isolates.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- New Proteins from Cold: Antibiofilm Activity of Cold-Azurin and PsyOmp38 Against Enterococcus faecalis and Klebsiella pneumoniae.Probiotics and antimicrobial proteins · 2026Article
- First comprehensive molecular and phenotypic insights into multidrug resistance and virulence in poultry-associated Enterococcus spp. in Algeria.Molecular biology reports · 2026Article
- Molecular Profiling of CRISPR-Cas System, Virulence Traits, and Antimicrobial Resistance inInternational journal of microbiology · 2026Article
- Resistance Landscape and Clonal Dynamics of ESKAPE Pathogens in Bloodstream Infections: A Multicenter Study from Mexico.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVarious factors, including virulence determinants, biofilm formation, and antimicrobial resistance, contribute to the severity of infections caused by Enterococcus spp.
methodsEnterococcus isolates were obtained from hospitalized patients in Yazd, Iran, and identified using microbiological and molecular tests. High-level resistance, biofilm formation, and the genes encoding virulence factors and resistance were investigated following standard methods.
resultsEnterococcus faecalis was the most prevalent species (60.7%), followed by Enterococcus faecium (30.4%). Linezolid was highly effective, with 94.6% of isolates being susceptible. However, more than 76% of isolates exhibited resistance to rifampin, erythromycin, tetracycline, and ciprofloxacin, and 94.6% were multidrug-resistant (MDR). Additionally, 39.3% of the isolates were vancomycin-resistant enterococci (VRE) with a MIC > 32 μg/mL, and the vanA gene was detected in 35.7% of the isolates. High-level resistance to gentamicin and streptomycin was seen in 60.7% and 50% of the isolates, respectively. The most prevalent aminoglycoside resistance gene was aph(3')-IIIa (62.5%) followed by ant(6')-Ia (58.9%), and aac(6')-Ie-aph(2″)-Ia (50%). The ant(3″)-Ia was found in only one isolate. Most of the isolates (87.5%) were biofilm producers, and the distribution of virulence-encoding genes was as follows: gelE (66.1%), efaA (57.1%), asa1 (51.8%), esp (25%), cylA (19.6%), and hyl (8.9%). Furthermore, the ace gene was present in 79.4% of E. faecalis isolates, while the fnm and acm genes were found in 76.5% and 23.5% of E. faecium isolates, respectively.
conclusionThe study highlights the significant role of notable drug resistance and the widespread presence of virulence traits in the development of enterococcal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.